Announcement: From January 2022 New Biotechnology will become an open access journal. Authors who publish in New Biotechnology will be able to make their work immediately, permanently, and freely accessible. New Biotechnology continues with the same aims and scope, editorial team, submission system and rigorous peer review. New Biotechnology authors will pay an article publishing charge (APC), have a choice of license options, and retain copyright to their published work. The APC will be requested after peer review and acceptance. The APC payment will be required for all accepted articles submitted after 1 October 2021. Please note: Authors who have submitted their paper on or before the 30th of September 2021, will have their accepted article published in New Biotechnology at no charge. Authors submitting their paper after this date will be requested to pay the APC. For more details visit our FAQs page. New Biotechnology is the official journal of the European Federation of Biotechnology (EFB) and is published bimonthly. It covers both the science of biotechnology and its surrounding business and financial milieu. The journal publishes peer-reviewed basic research papers, authoritative reviews, feature articles and opinions in all areas of biotechnology. It reflects the full diversity of current biotechnology science, particularly those advances in research and practice that open opportunities for exploitation of knowledge, commercially or otherwise, together with discussion and comment on broader issues of general interest and concern. The outlook is fully international. The scope of the journal includes the research, industrial, and commercial aspects of biotechnology, in areas including health care and pharmaceuticals; immunotherapy and diagnostics, biofuels, genetic engineering, genomics, synthetic biology, molecular technologies, environmental biotechnology, biobased materials, nanotechnology, food and agriculture, biocatalysis, bioremediation, process engineering, bioinformatics and databases, and digital technologies and artificial intelligence, where they relate to biotechnology.